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Summary Natural killer (NK) cell activity was measured in the peripheral blood mononuclear cells (PBMC)
from malnourished (MN) and well-nourished (WN) cancer patients and in healthy controls. A marked
depression of NK activity was observed in MN cancer patients with moderate protein-calorie malnutrition
(PCM), but not in WN cancer patients nor in the healthy controls. The depression of NK activity did not
correlate with the localisation of the tumour, patient's age or body weight reduction. The defective NK
activity of PBMC from MN cancer patients was restored to normal by rIL-2, but not by alfa-rIFN. Parenteral
nutrition of MN patients with the proper amount of proteins and calories quickly corrected the depressed NK
activity, indicating a central role of malnutrition in the genesis of their immune disfunction. PBMC from MN
cancer patients produced lower amounts of IL-2, as compared with healthy controls, when stimulated in vitro;
the most frequently affected were the responses to recall antigens such as influenza virus vaccine (FLU), while
those to allogeneic PBMC (ALLO) and phytohaemagglutinin (PHA) were less affected. However, for each
patient the ability to produce IL-2 in vitro did not correlate with NK activity, thus showing how the
impairment of NK activity is not subsequent to a decreased production of endogenous IL-2. In summary, it
can be concluded that malnutrition, rather than malignancy, plays a major role in the immune dysfunction of
cancer patients.
Protein calorie malnutrition (PCM), which is one of the
major and most characteristic problems of cancer bearing
patients, produces broad effects on the host immune
defences. Defects in humoral immunity, mucosal immunity
and phagocytic cell function have been identified, but the
weight of evidence suggests that cell-mediated immunity is
most profoundly impaired (Law et al., 1973; Keusch et al.,
1978; Gross & Newberne, 1980; Martin et al., 1983; Chan-
dra, 1989). In particular, depressed NK activity and unre-
sponsiveness to interferon have been reported in PBMC of
infants with PCM, as well as in acute starvation (Salimonou
et al., 1983; Schattner et al., 1990).
The aim of this research was to examine the role of PCM
in the genesis of tumour associated immunodeficiency.
Because of the importance of NK cells in the early defence
against infectious and malignant diseases and in the in vivo
destruction of circulating tumour emboli (Seaman et al.,
1987) we decided to analyse how PCM impairs NK cell
cytotoxicity in cancer bearing patients. Malnourished cancer
patients, showing about 10-20% reduction ofbody weight in
the last 6 months were studied; two control groups were
identified: (1) cancer patients without malnutrition and (2)
normal, healthy subjects. Both the basal NK activity of
PBMC and the effects of in vitro treatment with rIL-2 and
alfa-rIFN were examined. The ability of PBMC from the
same patients to produce IL-2 in response to a panel of
antigens was also measured in order to recognise any possible
correlation between NK and T helper (Th) cell functions.
Materials aifd methods
Special reagents
Highly purified human recombinant IL-2 (rIL-2) was provid-
ed by the Biogen (Cambridge, MA); recombinant human
Interferon alfa 2a (alfa-rIFN) was provided by Roche (Basel,
CH); anti-TAC and fluorescinated anti-Leu.7 monoclonal
antibodies (MoAB) were from Becton Dickinson (Sunnyvale,
CA).
Patients
The patients were hospitalised at the Istituto nazionale
Tumori of Milano (1987-1989) for cancer of various local-
isations. The patients were studied before receiving chemo- or
radiotherapy. Only patients exhibiting a documented reduc-
tion of the usual body weight of 10-20% in about 6 months,
were admitted to the study. None of the patients was obese
before the disease. Neoplastic patients without PCM were
studied and utilised as one of two control groups. A group of
37 healthy males and females, aged from 25 to 65, taken
from blood donors of the Istituto nazionale Tumori, was
evaluated as the second control group. All patients were
thoroughly examined for anthropometric, biochemical and
haematological parameters of nutritional status, which are
commonly used in clinical practice (Burbry & Mullen, 1984).
The characteristics ofmalnourished (MN) and well-nourished
(WN) patients were as follows:
WN cancer patients 20 subjects (14 males and six females)
aged from 41 to 70. No reduction of body weight during the
last 6 months.
MN cancer patients 39 subjects (27 males and 12 females)
aged from 41 to 89. Body weight reduction in the last six
months between 10 and 23%. Tumour localisation was as
follows: stomach, 16; liver, 6; pharynx and tongue, 5; pan-
creas, 3; colon-rectum, 3; others, 6.
The immune parameters of a group of ten MN cancer
patients, which underwent parenteral nutrition, were also
evaluated both prior and after the 10 day treatment period.
The parenteral nutrition regimen included a non protein
calorie load equal to 150% of the estimated resting energy
expenditure with a calorie to nitrogen ratio of 150:1 and was
delivered according to the commonly accepted guidelines
(Bozzetti, 1989).
Preparation ofeffector cells
PBMC were separated from heparinised blood samples by
density centrifugation on Ficoll-Hypaque gradients (Pharma-
cia fine Chemicals, Uppsala, Sweden). The separated cells
were washed twice in Hank's solution (Gibco, Grand Island,
NJ) and the number of viable cells was determined by trypan
blue exclusion and haemacytometer. Cells were resuspended
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in RPMI 1640 (Gibco, Grand Island, NY) containing 1%
glutamine.
Target cells
K562 cells (human myelogenous leukaemia with haemato-
genic potential) were grown in suspension in RPMI 1640 plus
10% FCS and were labelled by exposure for 1 h to 100 tlCi
Na [5"Cr]04.
Cytotoxicity assay
NK activity was assessed in a 18 h 5"Cr-release assay by
adding 3 x 103 target cells in 0.1 ml RPMI to 0.08 ml of
effector cells at varying concentrations, to obtain the desired
final effector to target cell ratios (E:T), 50:1, 25:1, 12:1, 6:1.
All assays were carried out in triplicate, in round-bottomed
microtitre plates (Linbro; Flow Laboratories, McLean, VA)
in a total volume of 0.2 ml. The microtitre plates were centri-
fuged for 3 min at 80g and then incubated for 18 h at 37°C
in a humidified 5% CO2 incubator. To harvest the assay, the
plates were centrifuged at 450g for 5 min and 0.1 ml of
supernatant was removed for counting. Spontaneous release
was evaluated by omitting effector cells, and maximum
release was determined by incubating targets in 2 N HCI,
which releases 75-95% of total counts. Percent cytotoxicity
was calculated as:
c.p.m. experimental - c.p.m. spontaneous x 100
c.p.m. maximum - c.p.m. spontaneous
rIL-2 and alfa-rIFN activated cytotoxicity
A total of 2 x 106 PBMC in 1 ml of RPMI were incubated
for 1 h at 370C with 1,000 U of alfa-rIFN. When treated with
rIL-2, 2 x 106 PBMC in 1 ml of RPMI were incubated at
37°C overnight with 600 U of rIL-2. Treated PBMC were
then tested for cytotoxicity in a 18 h 51Cr release assay as
described above.
NK cell immunophenotyping
To perform phenotypical analysis, PBMC were stained with
the MoAb anti-Leu.7 (Becton Dickinson, Sunnyvale, CA)
and examined with a fluorescence microscope.
Calculations andstatistical analysis ofdata
Student's t-tests were performed for the comparison of two
independent samples of unequal size as described by
Snedecor and Cochran (1980), and P values were determined.
Spearman's rank correlations and one-way analysis of
variance were calculated to evaluate the relationships
between NK activity depression and clinical parameters. Nor-
mal thresholds for basal or stimulated NK activity have been
calculated as mean values of control - 2 s.d.; all subjects
showing NK activity greater than two standard deviations
above the mean of controls were considered 'normally res-
ponsive'.
Results
Basal NK activity and NK counts
Basal NK activity expressed as percent lysis of K562 cells is
shown in Figure 1; E:T ratio of 50:1 was utilised for calcula-
tion. NK activity of MN cancer patients was significantly
lower than that of both WN cancer patients and healthy
controls (mean values ± s.d. 29.3 ± 14.89 vs 60.3 ± 7.38 and
65.2 ± 6.02 respectively; P<0.001 for both comparison). The
normal threshold calculated as the mean value of healthy
controls - 2 s.d., is equal to 53.24; only 2/34 MN cancer
patients and as much as 17/20 WN cancer patients showed
lytic activity over this threshold. This clearly indicates that
the NK activity was depressed in the great majority of MN
while it was normal in WN cancer patients.
The number of NK cells was evaluated by the MoAb
anti-Leu.7, which reacts with NK cells together with a vari-
able proportion of CD3 +, CD8 + T lymphocytes. The MN
cancer patients showed a normal number of Leu.7 positive
cells, expressed as a percentage of total PBMC (mean value
16.5 ± 5.7 s.d.); no significant differences were detected with
either one of the two control groups (WN cancer patients:
mean value 15.8 ± 8.3 s.d.; healthy subjects: mean value
17.3 ± 5.3 s.d.).
IL-2 production
For IL-2 production, 1 ml of PBMC was added per well to
24-well flat-bottom Linbro tissue culture plates (Flow Labor-
atories (Inc.) McLean, VA). The PBMC were cultured with-
out stimulation or were stimulated with (a) influenza virus
vaccine, prepared with a mixture ofA/Taiwan, A/Shangai, B/
Victoria, 24figml-' (final dilution 1:1,000); (b) a pool of
irradiated (5,000 rad) PBMC from two unrelated blood
donors (2 x 106well) and (c) PHA (Gibco, Grand Island,
NY) diluted 1:200. Foetal bovine serum was added to each
well (final dilution 1:20). Supernatants of stimulated and
unstimulated cultures were harvested 7 days later and frozen
at -20°C. For studies of IL-2 production, the anti-IL-2
receptor antibody, monoclonal anti-TAC, was added at the
initiation of culture at a final concentration of 10figml-', in
order to block IL-2 consumption (Uchiyama et al., 1981).
The supernatant IL-2 activity was assessed as the ability to
stimulate the proliferation of the IL-2 dependent cell line,
CTLL. This cell line is stimulated by human IL-2, but not by
human IL-4. Assay cultures consisted of 8 x 103 CTLL/well
and five successive 2-fold dilutions of supernatant. Twenty-
four hours later, the cultures were pulsed with 1 pCi of
3H-thymidine (ICN Radiochemicals, Irving, CA) and harvest-
ed 18 h later. Results are expressed as mean c.p.m. for three
replicate wells for a given supernatant dilution. Standard
errors were always < 10% of the mean values. The con-
centration of anti-Tac antibody used in the initial culture did




































Figure 1 Basal NK activity expressed as percentage lysis of
K562 cells, after 18 h incubation with PBMC from MN and WN
cancer patients or from healthy controls. Horizontal bars repre-
sent the normal basal threshold, calculated as mean value of
healthy control - 2 s.d. E:T ratio of 50:1 was utilised for calcula-
tion.
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Lack ofcorrelation between depressed NKactivity andsome
clinicalparameters
To determine whether the degree of NK activity reduction in
MN patients is related to any clinical parameter, we ana-
lysed, for each patient, multiple data: (1) site of the tumour,
(2) age; (3) body weight reduction. The analysis of variance
did not show any significant difference between NK activity
of MN cancer patients as related to the localisation of the
tumour (P = 0.45); similarly the Spearman's rank correlation
test indicated the absence of any significant correlation
between NK activity and age or percent weight loss (r = 0.04
and 0.14 respectively).
Stimulated NK activity
In order to evalute the responsiveness of NK cells to rIL-2
and alfa-rIFN, PBMC were incubated with these two activa-
tors for 18 and 1 h respectively, and the NK activity against
K562 cells was measured. IL-2 had a marked enhancing
effect on PBMC from MN cancer patients (Figure 2). The
basal vs IL-2 activated cytotoxicity expressed as percentage
lysis was equal to 33.45 ± 15.24 vs 72.30 13.83 (118% in-
crease) for MN cancer patients, to 60.00 ± 7.36 vs 81.25 ±
9.21 (37% increase) for WN cancer patients and to 64.95 ±
6.22 vs 88.68 ± 3.47 (36% increase) for healthy controls. The
responsiveness to alfa-rIFN was less marked (Figure 2); the
basal vs IFN activated cytotoxicity expressed as percentage
lysis was equal to 33.45 ± 15.24 vs 48.25 ± 17.20 (31% in-
crease) for MN cancer patients, to 60.00 ± 7.36 vs 76.60 ±
9.47 (29% increase) for WN cancer patients and to 64.95 ±
6.22 vs 82.32 ± 6.35 (27% increase) for healthy controls. The
normal thresholds for the basal and stimulated NK activity,
calculated as mean percentage cytotoxicity of healthy con-
trols- 2 s.d., were as follows: (1) 52.51 for basal NK activity;
(2) 81.74 for rIL-2 stimulated NK activity; (3) 69.62 for
alfa-rIFN stimulated NK activity. The incubation with rIL-2
increased the NK activity of PBMC from MN cancer
patients up to the normal basal threshold in 18/19 cases, and
up to the normal rIL-2 stimulated threshold in 4/19 cases. On
the contrary, after the incubation with alfa-rIFN only 8/19
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MN cancer patients showed an NK activity over the normal
basal threshold, and 0/20 over the normal alfa-rIFN activa-
ted threshold. It can be concluded that rIL-2, but not alfa-
rIFN, was able to restore the NK activity of MN cancer
patients to levels close to those of normal subjects.
IL-2production
To test the ability of PBMC to produce IL-2 in vitro in
response to different stimulators, PBMC were cultured for 7
days with FLU, ALLO and PHA, in presence of the MoAb
anti-TAC, to prevent IL-2 consumption. At the end of the
culture period the supernatants were harvested and tested for
IL-2 content by assessing their capacity to support the pro-
liferation of the IL-2 dependent CTLL cell line. Normalised
IL-2 responses expressed as absolute c.p.m. are shown in
Figure 3; supernatant dilution of 1:4 has been utilised for
calculation. The IL-2 responses are depressed in some but
not in all MN cancer patients.
The normal thresholds, calculated as mean value of abso-
lute c.p.m. of healthy controls - 2 s.d. were as follows: (1)
23,417 for ALLO; (2) 30,955 for PHA and (3) 14,192 for
FLU responses. As much as 14/20 and 13/20 patients as
concerns ALLO and PHA but only 8/20 patients as concerns
FLU showed a response over the normal threshold. It
appears that the responses to FLU were more frequently
affected in MN cancer patients, than those to ALLO and
PHA. No correlations were detected between the capacity to
produce IL-2 to FLU, ALLO or PHA and the NK activity.
Effects ofparenteral nutrition on NK activity
To further examine the influence of nutrition on NK activity,
the immunological status of a group of ten patients was
evaluated before and after 10 days of treatment. The results
are shown in Table I. In all patients NK activity quickly
improved after parenteral nutrition. The mean values of
cytotoxic activity, expressed as percentage lysis, increased
from 37.6 ± 8.7 to 54.5 ± 9.7 for basal, from 56.5 ± 9.9 to
70.3 ± 8.5 for alfa-rIFN stimulated and from 75.0 ± 8.4 to
82.9 ± 3.6 for rIL-2 stimulated activity. The normal thres-
MN patients WN patients Healthy controls
Figure 2 Effect of rIL-2 (top) and alfa-rIFN (bottom) stimulation on the NK activity of PBMC from MN and WN cancer
patients and from healthy controls. NK activity is expressed as percentage lysis and the E:T ratio 50:1 was utilised for calculation.
For each donor the NK activity prior (0) and after stimulation (A) is indicated. The horizontal lines represent the normal









































Figure 3 Normalised IL-2 production of PBMC cultures from
MN cancer patients and healthy controls, stimulated with ALLO,
FLU, and PHA, assessed by CTLL proliferation bioassay. The
data are expressed as absolute c.p.m.; supernatant dilution 1:4
was utilised for calculation. Horizontal bars represent the normal
basal threshold, calculated as mean value of healthy controls -
2s.d.
Table I NK activity prior and after 10 days ofparenteral nutrition
NKactivity expressed as % lysis Patient Before nutrition After nutrition
no. Basal Alfa-rIFN rIL-2 Basal Alfa-rIFN rIL-2
1 36 49 60 50 65 83*
2 30 66 71 49 86* 75
3 33 53 63 66* 85* 80
4 28 56 82* 40 64 84*
5 35 53 88* 48 58 89*
6 37 59 76 55* 68 86*
7 34 34 70 69* 69 81
8 52 62 80 59* 68 83*
9 41 61 78 52 66 83*
10 57* 72* 82* 69* 74* 85*
x 37.6 56.5 75.0 54.4 70.3 82.9
s.d. 8.7 9.9 8.4 9.7 8.5 3.6
Mean NKactivity ofcontrols expressed as % lysis
x 64.9 83.0 89.9 -
s.d. 6.3 6.6 4.0 - - -
Normal thresholds
x-2 52.3 69.8 81.9 - -
s.d.
Mean NKactivity ofMNpatients expressed as % ofcontrols
% 58 68 83 83 85 92
* Indicatethevalues overnormalthresholdcalculated as meanvalues
of controls -2 s.d.
holds, calculated as mean value of absolute c.p.m. of healthy
controls - 2 s.d. were as follows: (1) 52.3 for basal; (2) 69.8
for alfa-rIFN and (3) 81.9 for rIL-2 stimulated NK activity.
After parenteral nutrition, as many MN cancer patients as
5.10 for basal and 7/10 for rIL-2 stimulated NK activity, but
only 3/10 for alfa-rIFN stimulated NK activity showed a
response over the normal thresholds. It can be concluded
that parenteral nutrition corrected NK activity to normal in
several MN patients; the most sensitive to this correction was
the responsiveness to rIL-2 stimulation, while the most re-
fractory was that to alfa-rIFN stimulation.
Discussion
Our results show that (1) PCM in cancer bearing patients is
associated with a marked decrease of their NK cell activity as
compared to healthy controls (29.3 ± 14.9 vs 65.2 ± 6.0 per-
cent lysis, respectively) (Figure 1); (2) this depressed NK
activity is not correlated with the localisation of the tumour,
the patient's age or the weight loss; (3) functional activity,
but not the number, of the NK cells is decreased, as judged
by the percentage of PBMC stained by anti-Leu.7 MoAB; (4)
the depressed NK cell activity can be restored in vitro by
rIL-2 but not by alfa-rIFN (Figure 2); (5) parenteral nutri-
tion quickly corrects the depressed NK activity (Table I).
Following overnight incubation with rIL-2, the NK cell
activity of PBMC from MN cancer patients almost always
increases up to the normal basal threshold of healthy control
cells; in a few cases, such an increase is even greater, thus
reaching that of rIL-2 stimulated normal PBMC (Figure 2).
The rIL-2 stimulated PBMC from WN cancer patients
behave like those from controls. On the other hand, the
cytotoxic activity of PBMC from MN cancer patients is only
moderately enhanced by incubation with alfa-rIFN; in a few
cases it reaches the normal basal threshold and in no cases at
all it goes over the threshold of alfa-rIFN stimulated normal
PBMC (Figure 2). It can be concluded that rIL-2, but not
rIFN, is able to restore the NK activity of MN cancer
patients.
The impairment of NK activity in MN cancer patients is
rapidly corrected by nutritional repletion. After 10 days of
parenteral administration of proper amounts Qf protein and
calories, the basal NK activity shows a marked increase, if
compared to that observed prior to renutrition (mean values
from 58% to 83% ofhealthy controls prior and after renutri-
tion respectively); the rIL-2 stimulated activity is almost
always normalised while the alfa-rIFN stimulated activity is
normalised in a minority of cases, thus appearing more re-
fractory to correction. We are unable to explain the different
PBMC sensitivity of MN cancer patients to rIL-2 or to
alfa-rIFN, which was observed both prior and after nutri-
tional recovery. We recall that a decreased responsiveness to
IFN, often associated with a good reactivity to IL-2, has
been observed in' other clinical situations with PCM such as
malnourished infants or adults with liver cirrhosis (Charpen-
tier et al., 1984) or in several diseases with reduced NK cell
activity, such as EBV and HIV infections (Purtilo et al.,
1985; Rook et al., 1985) and in common variable hypo-
gammaglobulinemia (Clerici et al., 1988). In malnourished
children the nutritional recovery completely corrects both the
basal NK activity and the responsiveness to IFN (Salimonou
et al., 1983).
Since NK cells of MN patients with cancer do positively
respond to rIL-2 in vitro, we have hypothesised that their low
basal cytotoxicity could be a function of a decreased produc-
tion of endogenous IL-2. Therefore, the amount of IL-2
produced by PBMC stimulated in vitro, was measured by
means of a proliferation assay of a IL-2 dependent cell line
(CTLL). We evaluated the IL-2 production following stimu-
lation with FLU, ALLO and PHA as specified in Methods.
This panel of stimuli was selected because it permits the
analysis of several T helper/antigen presenting cell (Th/APC)
pathways. Indeed the responses to FLU require CD4 + Th
and autologous APC. Responses to ALLO can utilise both
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CD4 + and CD8 + Th together with allologous or auto-
logous APC; in contrast, the response to PHA utilises both
CD4 + and CD8 + Th, but is less dependent on APC. The
results show that the IL-2 production is decreased in some
but not in all MN cancer patients as compared to controls;
the most affected are the responses to recall antigen FLU,
while those to ALLO and PHA are less influenced. However,
the level of the IL-2 production does not correlate in any
case with both basal and rIL-2 or rIFN activated NK
activity. This suggests that the depression of NK activity in
MN cancer patients is not dependent from the decreased
production of endogenous IL-2.
In conclusion, our results show that malnutrition plays a
major role in the regulation of the immune response of
cancer bearing patients and that the impairment of natural
cytotoxicity, as reported in the literature, is more correctly
referable to PCM rather that to malignancy itself. The mech-
anism responsible of the depressed NK activity in MN cancer
patients is not known. In principle, it may be amenable to (1)
lack of essential nutrients for RNA and protein synthesis or
for other metabolic processes necessary both for NK func-
tion and activitation and (2) release of some specific factors
associated with cancer, such as TNF, which can cause con-
temporaneously PCM and NK activity depression (Beutler,
1988; Plata-Salaman et al., 1988; Vaisman, 1989; Gordon &
Wofsy, 1990). For the time being, we chose to explore this
latter hypothesis examining if changes in TNF production in
MN cancer patients, if present, may correlate with NK
activity depression.
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